Market Insight Reports

  Obstructive Sleep Apnea Market DelveInsight's Obstructive Sleep Apnea (OSA) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Obstructive Sleep Apnea (OSA), historical and forecasted epidemiology as well as the Obstructive Sleep Apnea (OSA) market trends in 7MM. NPC Marke DelveInsight's 'Niemann-Pick Disease Type C NPC Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease forecasted epidemiology Mineral Metabolism Disorder Market Mineral Metabolism Disorder Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Mineral Metabolism Disorder forecasted epidemiology Metastatic Merkel Cell Carcinoma Market Metastatic Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast report delivers an understanding of the Metastatic Merkel Cell Carcinoma forecasted epidemiology Lambert-Eaton My

  Data of Phase I study (NCT03260491) Dose expansion cohort Phase I study of patitumab deruxtecan in patients with EGFR activating mutated squamous or non-squamous NSCLC with disease progression during or after systemic treatment for locally advanced or metastatic disease (Abstract # 9017) Patritumab deruxtecan is a newer generation ADC that has elicited encouraging responses with acceptable safety in patients with EGFR TKI-resistant, EGFRm NSCLC. In 2021, the drug also got Breakthrough Therapy Designation (BTD) in EGFRm NSCLC patients based on the dose-escalation portion and two cohorts of a three-cohort phase I study. On January 28, 2022, the data cut-off date, the confirmed overall response rate (ORR) by blinded independent central review (BICR) per RECIST 1.1 was 28.6% among patients with identified genomic driver alterations (n = 21). The disease control rate (DCR) in this cohort of patients was 76.2%, and the median time to response was 2.8 months. The median duration of respon

  Treatment-resistant depression (TRD) typically refers to inadequate response to at least one antidepressant trial of adequate doses and duration. Treatment-resistant depression is a relatively common occurrence in clinical practice, with up to 50–60% of the patients not achieving adequate response following antidepressant treatment. Treatment-Resistant Depression Epidemiology Segmentation in the 7MM  Total Diagnosed Prevalent Cases Treatment-Resistant Depression Age-Specific Cases of Treatment-Resistant Depression Gender-specific Cases of Treatment-Resistant Depression Treatment-Resistant Depression Epidemiological Insights Observed in the 7MM (2021) The total prevalent cases of Treatment-Resistant Depression in the 7MM were estimated to be 5.8 million. The total prevalent cases of Treatment-Resistant Depression in the US were estimated to be 3.9 million. The total prevalent cases of Treatment-Resistant Depression in Germany was found to be 558k and in Italy, they were found to be 1

           ASCO 2022: Junshi’s domestic Toripalimab’s Highlight Toripalimab and cetuximab in combination have shown preliminary safety and efficacy in treating platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma . Inhibitory mechanism of toripalimab: Programmed cell death-1 receptor antagonists, antibody-dependent cell cytotoxicity, and T lymphocyte stimulants. Angiogenesis inhibitors, antibody-dependent cell cytotoxicity, and antagonists of the epidermal growth factor receptors make up Cetuximab's mode of action. A recombinant humanised anti-PD-1 monoclonal antibody for injection that targets various malignant tumours is called toripalimab. Based on Phase I/II clinical trials, the company disclosed its preliminary findings about the safety of toripalimab plus cetuximab. Junshi Biosciences displayed their pipeline in ASCO 2022 on June 6, 2022. Preliminary findings of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic HNSC

  ASCO 2022: Sermonix’s Lasofoxifene Phase II study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre-and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies. The ELAINEII study evaluated lasofoxifene plus abemaciclib in ER+/HER2− metastatic breast cancer who had acquired ESR1 mutations on circulating tumor DNA (ctDNA) after progressing on 1 or 2 prior lines of therapy, 1 of which could have been chemotherapy. Lasofoxifene has been granted a Fast Track Designation by the FDA to treat women who have ER+ metastatic breast cancer with an ESR1 mutation. The objective response rate (ORR) was 50% in a group of patients who had advanced on 1 or 2 prior lines of therapy, according to data given at the ASCO 2022 Annual Meeting, with a 24-week clinical benefit rate (CBR) of 69%. The median PFS after censoring was 55.7, or roughly 13 months. Nine patients (50%) with detectable target lesi